RAPGEF3 and Hepatic cysts: While this suggests targeting PKA rather than Epac as a potential new avenue in the treatment of PKD [143], both PKA and Epac were involved in promoting cAMP-stimulated growth of cholangiocyte-derived liver cysts via the MEK-ERK1/2 cascade in a rat homologous model of autosomal recessive PKD [144].